Home
NewsNewsFairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
In a significant move for the reproductive medicine industry, Fairfax Cryobank and IVI RMA North America have officially announced a strategic partnership designed to Fairfax IVI expand donor sperm access. This collaboration seeks to provide individuals and couples with high-quality donor sperm, significant savings, and premium support services as they pursue their family-building goals.
Through this new alliance, IVI RMA North America patients will gain direct access to Fairfax Cryobank’s extensive nationwide network of diverse donors. Beyond increasing the availability of donor sperm, the partnership introduces various programmes aimed at enhancing financial accessibility and overall value for patients. Key benefits include personalised guidance, genetic compatibility insights, and flexible programme options tailored to the unique needs of each family.
To ensure a seamless experience, Fairfax Cryobank will manage the shipping and secure storage of samples while providing dedicated support throughout the process. The integration of these services into IVI RMA’s clinical framework is intended to reduce the logistical and emotional complexities often associated with fertility treatments.
Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America, highlighted the importance of this collaboration for patient care: “This partnership with Fairfax Cryobank is an important advancement in our mission to expand access to high-quality, patient-centred fertility care to all Americans. By combining IVI RMA's clinical expertise with Fairfax Cryobank's high-quality diverse donor sperm and value-added services, we are reducing the financial and emotional barriers to reproductive treatment and empowering more individuals and families to pursue parenthood with greater confidence and clarity.”
The partnership will see Fairfax Cryobank’s donor selection process fully integrated into the personalised fertility treatment plans at IVI RMA’s 27 North American laboratories. This streamlined approach includes coordinated lab services and genetic counselling, allowing patients to make more informed clinical decisions. Furthermore, both organisations have reaffirmed their commitment to inclusive services, supporting LGBTQ+ families, single moms by choice, and any individuals requiring donor sperm to build their families. Dr. Harvey Stern, MD, PhD, Medical Director of Fairfax Cryobank, expressed his pride in the joint effort:
“We are proud to partner with IVI RMA North America to deliver a seamless patient-centred experience for those building their families. By combining our extensive donor network, secure storage, and personalised guidance with IVI RMA's clinical leadership and advanced IVF laboratories, we are ensuring patients receive trusted support at every step of their journey.”
Fairfax Cryobank, established in 1986, is renowned for its comprehensive donor screening and testing procedures, operating seven locations across the United States to serve recipients globally. IVI RMA North America, which includes Reproductive Medicine Associates, Boston IVF, and TRIO, has facilitated the birth of over 220,000 babies to date. As part of IVI RMA Global, the network remains a leader in evidence-based fertility solutions, employing over 6,000 people across 15 countries.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
